A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

Brief description of study

The purpose of this research study is to: 1) evaluate how well IMR-687 is tolerated in subjects with β-thalassemia and how safe it is, 2) measure the amount of IMR-687 in your blood and 3) evaluate what the drug does to the red blood cells and other blood markers associated with your disease.

Drug IMR-687 is not FDA approved for use.

This study will look at two different dose levels of IMR-687 and compare how these work to a placebo, which is a substance that looks like an active drug but has no active drug in it.

This study is a randomized trial which means that participants will be randomly assigned to one of the study drug doses (high dose or low dose of IMR-687, or placebo).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    beta-thalassemia
  • Age: Between 18 Years - 65 Years
  • Gender: All


Updated on 02 Feb 2021. Study ID: 844255

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center